At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Carboplatin AUC +1 moredrug
Likely dose
Abraxane 100mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
In Brief
A Phase 2 clinical trial evaluating Carboplatin AUC and Abraxane for Endometrial Cancer. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety of treatment with carboplatin and Abraxane in this patient population and determine the nature and degree of toxicities following treatment. The single stage open label Phase II feasibility study is designed to estimate the proportion of patients who can tolerate the proposed regimen for 6 cycles with no more than two dose level reductions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJul 2016
Primary CompletionAug 2018
Study CompletionMar 2020
TodayJul 2026
First PostedApr 20, 2016
Enrollment StartJul 1, 2016
Primary CompletionAug 17, 2018
Study CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.2 years ago
Interventions
Carboplatin AUCdrug
Abraxanedrug
100mg/m2